JAK-IN-25
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC50 of 28 nM. JAK-IN-25 has the potential for cancer research[1].
Product Specifications
CAS Number
[2127110-22-7]
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jak-in-25.html
Purity
98.44
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=NN2C=C(C3=CN(CC4=CC=C(C=C4)OC)N=C3)NC(C2=C1)=O)OC
Molecular Formula
C19H17N5O4
Molecular Weight
379.37
References & Citations
[1]Matthew Frank Brown, et al. Pyrazolo[1,5-a]pyrazin-4-yl derivatives. US20230045252A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3; Tyk2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ERR-alpha Recombinant Antibody, AbBy Fluor™ 594 Conjugated
ERR-alpha Recombinant Antibody, AbBy Fluor™ 594 Conjugated
Recombinant Medicago truncatula Probable histone H2B.3